Advertisement

Topics

Phase 1/2 data show Roche's entrectinib shrinks tumours with NTRK, ROS1 or ALK gene fusions in children & adolescents

06:41 EDT 17 May 2019 | Pharmafile

Roche has unveiled new Phase 1/2 data for its selective tyrosine kinase inhibitor entrectinib, demonstrating its ability to shrink recurrent or refractory solid tumours with and without neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kinase (ALK) gene fusions in adolescent and child patients.

In the trial, all 11 participants entrectinib  responded to the drug, and two even achieved a complete response. Five of the participants, who had primary high-grade tumours of the central nervous system, also registered an objective response.  

read more

Original Article: Phase 1/2 data show Roche's entrectinib shrinks tumours with NTRK, ROS1 or ALK gene fusions in children & adolescents

NEXT ARTICLE

More From BioPortfolio on "Phase 1/2 data show Roche's entrectinib shrinks tumours with NTRK, ROS1 or ALK gene fusions in children & adolescents"

Advertisement
Quick Search
Advertisement
Advertisement